Post-translational regulation of gene expression using the ATF4 oxygen-dependent degradation domain for hypoxia-specific gene therapy

Journal of Drug Targeting

Volumn 21, Issue 9, 2013, Pages 830-836

  Cho, Su Hee ^a   Oh, Binna ^a   Kim, Hyun Ah ^a   Park, Jeong Hyun ^b   Lee, Minhyung ^a  

^a Hanyang University   (South Korea)

^b Inje University   (South Korea)

Author keywords

Activating transcription factor 4; Gene regulation; Gene therapy; Hypoxia; Post translational regulation

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; CASPASE 3; CASPASE 7; COMPLEMENTARY DNA; GANCICLOVIR; LUCIFERASE; MESSENGER RNA; THYMIDINE KINASE;

ANIMAL CELL; ARTICLE; CANCER GENE THERAPY; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GLIOMA CELL; HERPES SIMPLEX VIRUS; HYPOXIA; HYPOXIC CELL; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; OXYGEN DEPENDENT DEGRADATION DOMAIN; PLASMID; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROCESSING; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACTIVATING TRANSCRIPTION FACTOR 4; ANIMALS; APOPTOSIS; CELL CULTURE TECHNIQUES; CELL HYPOXIA; CELL LINE, TUMOR; GENE EXPRESSION REGULATION; GENETIC THERAPY; IN SITU NICK-END LABELING; LUCIFERASES; MICE; OXYGEN; PLASMIDS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EID: 84885635128     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2013.829073     Document Type: Article

References (23)

1. Kim HA, Mahato RI, Lee M. Hypoxia-specific gene expression for ischemic disease gene therapy. Adv Drug Deliv Rev 2009;61: 614-22
2. Rait AS, Pirollo KF, Xiang L, et al. Tumor-Targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels. Mol Med 2002;8:475-86
3. Choi BH, Ha Y, Huang X, et al. Hypoxia-inducible expression of vascular endothelial growth factor for the treatment of spinal cord injury in a rat model. J Neurosurg Spine 2007;7:54-60
4. Lee M, Bikram M, Oh S, et al. Sp1-dependent regulation of the RTP801 promoter and its application to hypoxia-inducible VEGF plasmid for ischemic disease. Pharm Res 2004;21:736-41
5. Lee M, Rentz J, Bikram M, et al. Hypoxia-inducible VEGF gene delivery to ischemic myocardium using water-soluble lipopolymer. Gene Ther 2003;10:1535-42
6. Choi BH, Ha Y, Ahn CH, et al. A hypoxia-inducible gene expression system using erythropoietin 30 untranslated region for the gene therapy of rat spinal cord injury. Neurosci Lett 2007;412: 118-22
7. Lee M, Choi D, Choi MJ, et al. Hypoxia-inducible gene expression system using the erythropoietin enhancer and 30-untranslated region for the VEGF gene therapy. J Control Release 2006;115:113-19
8. Fomicheva EV, Turner II, Edwards TG, et al. Double oxygensensing vector system for robust hypoxia/ischemia-regulated gene induction in cardiac muscle in vitro and in vivo. Mol Ther 2008;16: 1594-601
9. Harada H, Hiraoka M, Kizaka-Kondoh S. Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res 2002;62:2013-18
10. Harada H, Kizaka-Kondoh S, Itasaka S, et al. The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-Time imaging of absolute HIF-1 activity in tumor xenografts. Biochem Biophys Res Commun 2007;360:791-6
11. Inoue M, Mukai M, Hamanaka Y, et al. Targeting hypoxic cancer cells with a protein prodrug is effective in experimental malignant ascites. Int J Oncol 2004;25:713-20
12. Kim HA, Kim K, Kim SW, et al. Transcriptional and posttranslational regulatory system for hypoxia specific gene expression using the erythropoietin enhancer and the oxygen-dependent degradation domain. J Control Release 2007;121:218-24
13. Kim HA, Lim S, Moon HH, et al. Hypoxia-inducible vascular endothelial growth factor gene therapy using the oxygen-dependent degradation domain in myocardial ischemia. Pharm Res 2010;27: 2075-84
14. Koshikawa N, Takenaga K. Hypoxia-regulated expression of attenuated diphtheria toxin A fused with hypoxia-inducible factor-1alpha oxygen-dependent degradation domain preferentially induces apoptosis of hypoxic cells in solid tumor. Cancer Res 2005;65:11622-30
15. Won YW, Lee M, Kim HA, et al. Post-Translational regulated and hypoxia-responsible VEGF plasmid for efficient secretion. J Control Release 2012;160:525-31
16. Blais JD, Filipenko V, Bi M, et al. Activating transcription factor 4 is translationally regulated by hypoxic stress. Mol Cell Biol 2004; 24:7469-82
17. Koditz J, Nesper J, Wottawa M, et al. Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor. Blood 2007;110: 3610-17
18. Rzymski T, Milani M, Singleton DC, et al. Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. Cell Cycle 2009;8:3838-47
19. Ye J, Koumenis C. ATF4, an ER stress and hypoxia-inducible transcription factor and its potential role in hypoxia tolerance and tumorigenesis. Curr Mol Med 2009;9:411-16
20. Bao R, Selvakumaran M, Hamilton TC. Targeted gene therapy of ovarian cancer using an ovarian-specific promoter. Gynecol Oncol 2002;84:228-34
21. Cao G, Kuriyama S, Gao J, et al. Gene therapy for hepatocellular carcinoma based on tumour-selective suicide gene expression using the alpha-fetoprotein (AFP) enhancer and a housekeeping gene promoter. Eur J Cancer 2001;37:140-7
22. Su H, Lu R, Chang JC, et al. Tissue-specific expression of herpes simplex virus thymidine kinase gene delivered by adeno-Associated virus inhibits the growth of human hepatocellular carcinoma in athymic mice. Proc Natl Acad Sci USA 1997;94:13891-6
23. Suzuki S, Tadakuma T, Kunitomi M, et al. Liposomemediated gene therapy using HSV-TK/ganciclovir under the control of human PSA promoter in prostate cancer cells. Urol Int 2001;67: 216-23